Multi-omics pan-cancer analyses identify MCM4 as a promising prognostic and diagnostic biomarker

被引:0
作者
Yanxing Li
Wentao Gao
Zhen Yang
Zhenwei Hu
Jianjun Li
机构
[1] Xi’an Jiaotong University Health Science Center,Department of Cardiology
[2] Jincheng People’s Hospital Affiliated to Changzhi Medical College,undefined
来源
Scientific Reports | / 14卷
关键词
MCM4; Multi-omics; Pan-cancer; Bioinformatics; Immune infiltration; Prognosis; Biomarker;
D O I
暂无
中图分类号
学科分类号
摘要
Minichromosome Maintenance Complex Component 4 (MCM4) is a vital component of the mini-chromosome maintenance complex family, crucial for initiating the replication of eukaryotic genomes. Recently, there has been a growing interest in investigating the significance of MCM4 in different types of cancer. Despite the existing research on this topic, a comprehensive analysis of MCM4 across various cancer types has been lacking. This study aims to bridge this knowledge gap by presenting a thorough pan-cancer analysis of MCM4, shedding light on its functional implications and potential clinical applications. The study utilized multi-omics samples from various databases. Bioinformatic tools were employed to explore the expression profiles, genetic alterations, phosphorylation states, immune cell infiltration patterns, immune subtypes, functional enrichment, disease prognosis, as well as the diagnostic potential of MCM4 and its responsiveness to drugs in a range of cancers. Our research demonstrates that MCM4 is closely associated with the oncogenesis, prognosis and diagnosis of various tumors and proposes that MCM4 may function as a potential biomarker in pan-cancer, providing a deeper understanding of its potential role in cancer development and treatment.
引用
收藏
相关论文
共 193 条
[71]  
Sheng Y(2022)Pathogenesis of triple-negative breast cancer Annu. Rev. Pathol. 17 181-3361
[72]  
Xie L(2021)Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities Cancer Cell 39 346-3027
[73]  
Li T(2021)Cancer stem cell-immune cell crosstalk in tumour progression Nat. Rev. Cancer 21 526-W514
[74]  
Yang LH(2020)The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy Nat. Rev. Cancer 20 662-W560
[75]  
Gan N(2013)Innate and adaptive immune cells in the tumor microenvironment Nat. Immunol. 14 1014-658
[76]  
Du Y(2021)Tumor-infiltrating natural killer cells Cancer Discov. 11 34-27
[77]  
Zhang W(2012)MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans J. Clin. Investing. 122 814-2077
[78]  
Zhou J(2012)Unraveling human natural killer cell deficiency J. Clin. Investig. 122 798-481
[79]  
Watanabe E(2021)Diversity and biology of cancer-associated fibroblasts Physiol. Rev. 101 147-4202
[80]  
Ohara R(2013)Targeting cell cycle regulation in cancer therapy Pharmacol. Ther. 138 255-W64